Skip to main content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Policy & Regulation

Reports

Displaying 61 - 70 of 887. 10 per page. Page 7.

Advanced Search
ASPE Issue Brief

Changes in the List Prices of Prescription Drugs, 2017-2023

Drug manufacturers may change the list prices of their drugs at any time after launch. Over the period from January 2022 to January 2023, more than 4,200 drug products had price increases, of which 46 percent were larger than the rate of inflation. The average drug price increase over the course of the period was 15.2 percent, which translates to $590 per drug product.
Fact Sheet

Inflation Reduction Act Research Series: Projected Impacts for Asian, Black, and Latino Medicare Enrollees

The Inflation Reduction Act (IRA) is helping people with Medicare afford their medications, including the 2.1 million Asian, 5.8 million Black, and 5.3 million Latino Part D enrollees. These fact sheets review existing research to present the projected impacts of key IRA Medicare drug-related provisions for these populations.
Report

FY 2023 HHS Capacity Assessment Update

The Foundations for Evidenced-Based Policymaking Act of 2018 (Evidence Act) provided an important opportunity to Federal Agencies to assess and improve, where needed, their evaluation and other evidence building activities.
Fact Sheet, Report

Inflation Reduction Act Research Series: Understanding Development and Trends in Utilization and Spending for Drugs Selected Under the Medicare Drug Price Negotiation Program

The Inflation Reduction Act (IRA) authorizes the Secretary of the Department of Health and Human Services (HHS) to negotiate prices directly with participating manufacturers for selected drugs that are high expenditure, single source drugs without generic or biosimilar competition.
ASPE Issue Brief

Helping People with Low Incomes Navigate Benefit Cliffs: Lessons Learned Deploying a Marginal Tax Rate Calculator

This project developed a calculator to help people anticipate how a change in earnings from employment would affect their net income, and in so doing, provide public benefit recipients with their estimated effective marginal tax rate on new earnings. Key Points:

National Uninsured Rate Reaches an All-Time Low in Early 2023

This Data Point examines new National Health Interview Survey (NHIS) data to assess recent changes in health coverage for the population. The most recent data finds that the national uninsured rate for all ages declined 1.9% from 2019 to 2022, with early 2023 data showing even greater decreases reaching an all-time low national uninsured rate of 7.7%.
Fact Sheet

State Fact Sheets: Impacts of the IRA and ACA on Lowering Health Care Costs

Expanding access to high-quality, affordable health care has been a priority of the Biden-Harris Administration.
Report

Updated Medicare FFS Telehealth Trends by Beneficiary Characteristics, Visit Specialty and State, 2019-2021

This research report updates prior reports on Medicare FFS telehealth trends during the COVID-19 public health emergency with data through end of 2021, by beneficiary characteristics, visit specialty and geography including by state. Medicare telehealth flexibilities during the COVID-19 pandemic continued to encourage use of telehealth among Medicare beneficiaries in 2021.
Report

State Medicaid Telehealth Coverage Policy Decisions Since the COVID-19 Public Health Emergency

ASPE contracted with RAND Health Care to catalogue and assess state changes to Medicaid telehealth policies during the COVID-19 PHE through May 2022 and identify the driving circumstances, motivations, and evidence supporting telehealth policy decisions during the COVID-19 Public Health Emergency (PHE).
Report, Report to Congress

Evaluation of the Impact of the No Surprises Act on Health Care Market Outcomes: Baseline Trends and Framework for Analysis - Report One

This first report focuses largely on establishing a baseline and a framework for further evaluation.